Extracellular Vesicle-Based Detection of Pancreatic Cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, necessitating early detection before metastasis.
• Current diagnostic methods and biomarkers for PDAC and its precursor lesions are limited.
• ADAM8 expression is elevated in PDAC and linked to reduced patient survival.

Purpose of the Study:

• To evaluate ADAM8-positive extracellular vesicles (EVs) and their associated microRNAs (miRNAs) as biomarkers for distinguishing PDAC and precursor lesions from healthy controls.
• To investigate the diagnostic potential of ADAM8 and specific miRNAs (miR-720, miR-451) in serum samples.

Main Methods:

• EVs were isolated from serum of PDAC patients, individuals with precursor lesions, and healthy controls.
• EVs were characterized using Nanoparticle Tracking Analysis and electron microscopy.
• ADAM8 expression on EVs was quantified by Flow Cytometry (FACS).
• Serum miRNA levels (miR-720, miR-451) were analyzed using quantitative Polymerase Chain Reaction (qPCR).
• Statistical analysis included Wilcoxon rank test and Receiver Operating Characteristic (ROC) curves.

Main Results:

• Significant enrichment of ADAM8 was observed on EVs from PDAC and precursor lesion patients compared to healthy individuals (p = 0.0005).
• Serum levels of miR-451 were significantly higher, and miR-720 were significantly lower in PDAC patients versus healthy controls.
• The combination of ADAM8-positive EVs and specific miRNAs demonstrated high diagnostic accuracy (AUC = 0.93 for miR-451, AUC = 1.00 for miR-720) in discriminating PDAC from controls.

Conclusions:

• ADAM8-positive EVs and their cargo miRNAs (miR-720, miR-451) show promise as a diagnostic biomarker set for PDAC.
• This biomarker panel could aid in the early screening of individuals at risk for pancreatic cancer.
• Further validation is warranted for clinical application in PDAC detection.